Press release: Uppsala,
Second quarter 2021
- Net sales amounts to KSEK 33 (0)
- Earnings for the period amounts to KSEK -5,503 (-3,152).
-
Earnings per share
SEK -0.09 (-0.18)
January -
- Net sales amounts to KSEK 69 (0)
- Earnings for the period amounts to KSEK -13,971 (-9,724).
-
Earnings per share
SEK -0.26 (-0.57)
Statement from the CEO
After a winter and spring with intensive development work, we recently got the results from our effect studies performed in collaboration with Pelvipharm in
DICOT'S AMBITION is to develop a leading drug to treat erectile dysfunction. This means that our future product needs to display unique features which are better than the treatments available today, where long-term effect perhaps is the foremost.
PROFESSOR
IN ORDER TO GET APPROVAL TO START CLINICAL TRIALS data from the early academic research needs to be complemented with data from well-established and validated animal models. During the spring, we have therefore continued to work with Pelvipharm and can now report truly gratifying results. The effect of LIB-01 lasts for at least seven days and increases up until day seven. This is a major breakthrough for Dicot in the development of a new drug with a long duration of action. Professor
IT´S AN HONOR FOR ME to continue the work of Professor
DICOT NOW REINFORCES THE COMPETENCE within the company and has recruited
WITH THE FANTASTIC RESULTS from the collaboration with Pelvipharm and the reinforced team backing us up, I have great faith in the continued work this autumn.
For further information, please contact:
Göran Beijer CEO
Tel: +46 706 63 60 09
Email: goran.beijer@dicot.se
Jessica Roxhed, CFO
Tel: +46 70-394 94 98
Email: jessica.roxhed@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
https://news.cision.com/dicot-ab--publ-/r/summary-of-interim-report-january---june-2021--dicot-ab,c3403019
https://mb.cision.com/Main/17172/3403019/1458865.pdf
https://mb.cision.com/Public/17172/3403019/befbb9a361bfdbbc.pdf
(c) 2021 Cision. All rights reserved., source